is...Long
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
#dcvax #allsolidtumors $nwbo #gbm https://t.co/3s1ufpU6WA
— Peter Davis (@peter_brit) November 3, 2023
"This case is also a warning to every fraudster who thinks they’re untouchable, that their crimes are too complex for us to catch, that they are too powerful to prosecute, or that they are clever enough to talk their way out of it if caught. Those folks should think again, and cut it out. And if they don’t, I promise we’ll have enough handcuffs for all of them"
Talking tough but on a daily basis the likes of Citadel et al continue to rob investors blind laughing all the way to the bank.
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 3, 2023
And so it begins.... the race is on. We know who Merck and perhaps will choose to partner in order to enhance their CAR T-cell treatments. $nwbo will make announcements soon.
Kite and Epic Bio Announce Collaboration to Develop New Cell…
#dcvax #allsolidtumors $nwbo #GBM_START
— Peter Davis (@peter_brit) November 3, 2023
Advancing cell and gene therapies: Key takeaways from ASGCT’s 5th Annual Policy Summit Opinion
Volume 31, Issue 11, 1 November 2023https://t.co/bT0DDxhBIk pic.twitter.com/5P25aMHVki
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 3, 2023
Some interesting points highlighted in presentation https://t.co/GYbpPvOfZf pic.twitter.com/g8BNx7jUDL
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 3, 2023
Interesting findings from survey. It just reiterates how badly patients need DCVax® paradigm-shifting platform to be expedited through the Regulator's approval framework.
Exclusive Orphan Drugs Industry Survey Results: Desire to Treat Rare… pic.twitter.com/Zl5EkhSang
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 3, 2023
Citadel's Griffin wants to take note, all it takes is one whistle blower to 'grow a conscience' or even just see the writing on the wall and opt to secure their financial future with a SEC Whistle blower award.
The clock is ticking and $nwbo… pic.twitter.com/huVimgaZ6v
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 2, 2023
Scientists employ AI to predict brain cancer outcomes. Stanford Medicine scientists and colleagues create an algorithm that could help physicians better understand and target complicated brain tumors.
A new view on glioblastoma
Even after…
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 2, 2023
OCTOBER 2, 2023 - Editors' notes Single set of criteria to assess progression in glioma aims to speed discovery of new medicineshttps://t.co/9vCpAQQ1st
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 2, 2023
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020
Neuro-Oncology, Volume 25, Issue Supplement_4, October 2023https://t.co/1vslxfD1UR pic.twitter.com/yTW1r69IZN
#dcvax #allsolidtumors $nwbo #GBM
— Peter Davis (@peter_brit) November 2, 2023
Interesting findings from UCLA..https://t.co/iwrv5o6EEO pic.twitter.com/WWCZ1J8A3z
#dcvax #allsolidtumors $nwbo #gbm https://t.co/Yly10gid82
— Peter Davis (@peter_brit) November 2, 2023
$NWBO
— hoffmann6383 (@hoffmann6383) November 1, 2023
When you do a search for the NICE recommended treatment options for rGBM you get the below results.
The UK needs more options for both nGBM and rGBM patients.
Approval of #DCVax-L can't happen soon enough. pic.twitter.com/92e3z1rcCl
You guys must have read this before. I feel so excited about the biomarker analysis adopted in the DCVax-L trials that I never get tired of repeating it. As mentioned in the Nature preprint, Dr. Liau found one specific biomarker related to significant OS.
— d_stock (@d_stock07734) November 1, 2023
If the difference in that biomarker before and after the treatment is greater than 0.2, then significant OS can be guaranteed to certain extent. Here are the differences in biomarkers for four patients who are alive today. pic.twitter.com/16zwcryhv6
— d_stock (@d_stock07734) November 1, 2023
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 1, 2023
Treatments such as DCVax® providing personalized immune therapies for solid tumor cancers could see benefit from this technology:-
'Personalised treatment'
About 4,300 people in England are diagnosed with this type of cancer each year.
Prof…
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 1, 2023
"A biosimilar is a biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA"
"Biologicals are a diverse group of medicines which includes vaccines,… https://t.co/76Cmhww5Tj
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) October 31, 2023
Dr Zavoico on the scientific Scientific Organizing Committee
Presentation topics include Cancer vaccines
I do not believe the full list of presenters has been announced yet.
Frontiers in Cancer Immunotherapy 2024
May 21-23, 2024
"In… pic.twitter.com/mq0EA4Ka6X
#dcvax #allsolidtumors $nwbo #gbm pic.twitter.com/ZvbifjIVgC
— Peter Davis (@peter_brit) October 31, 2023
In precisely two weeks, on November 14th, oral arguments are scheduled in $NWBO litigation concerning market manipulation, specifically addressing issues like spoofing and potentially mentioning naked shorting by market makers. I am very curious as to what critical information the legal team from Cohen Milstein will present to the judiciary, and whether the company might unveil significant regulatory and other updates in the same time frame to bolster its defense.
Subsequently, on November 16th, Dr. Steven Brem from the University of Pennsylvania, the third author of the heralded JAMA Oncology paper, will chair and moderate a session at the Society for Neuro-Oncology 2023 Conference #SNO2023. The session, titled "Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches," promises to shed light on groundbreaking treatments in glioblastoma care. https://lrn.peerview.com/150208821_1/150208821_1_p1/stage1reg?CountryID=US&AudienceID=Twitter&Promocode=815&ProjectNumber=150208821_1
One day later, on November 17th, Dr. Bosch will showcase an essential poster focusing on DCVax. That week will be particularly interesting.
https://twitter.com/BIO99_BIO99/status/1719262841679847665
#dcvax #allsolidtumors $nwbo #GBM_START
— Peter Davis (@peter_brit) October 30, 2023
Advent current job vacancies:-
QC Scientist II Sawston Quality Control
Quality Assurance Compliance Manager Sawston
Quality Assurance Senior Quality Assurance Compliance Officer Sawston pic.twitter.com/0GSm3CI3ml
I was buying all afternoon along with much bigger buyers. I posted my reasons the night before especially that I believe they’ve likely finished mfg optimization; big $ knows they’ll be approved in all jurisdictions so the MAA isn’t their signal to jump; mfg scaleability is
— Gregory Zivic, MD (@metacollectiveG) October 28, 2023
Never get tired of reading the trial design. IMO, people can invest heavily solely based on the trial design. Not to mention we have other plenty indications that DCVAX-L is going to revolutionize cancer treatment. pic.twitter.com/xrapp1FKRJ
— d_stock (@d_stock07734) October 28, 2023
#dcvax #allsolidtumors $nwbo #gbm pic.twitter.com/ujMOMBVr0O
— Peter Davis (@peter_brit) October 29, 2023
I assume $NWBO plans to market their product in the US. This requires a USAN [1]. A USAN requires a successful INN review [2]. Following a successful INN review, a USAN adoption occurs the last Wednesday of each month [2]. This means November 29th in $NWBO's case. $NWBO may use… pic.twitter.com/fxaqRlRYsG
— hoffmann6383 (@hoffmann6383) October 27, 2023
$NWBO #DCVax-L & #DCVax-Direct are tumor & tissue agnostic. Both have treated dozens of different solid tumor cancer types & extended OS in early phase trials & compassionate use. ADCs only target 1 or 2 tumor antigens. DCVax target all the hundreds of cancer tumor antigens: pic.twitter.com/KVC9mo4Q6a
— ATLnsider (@ATLnsider) October 27, 2023
Dendritic cells are so exciting, I have been publishing on them for 20 years now...
— Dr. Thomas Ichim (@exosome) October 26, 2023
Back in 2003 we showed permanent immunological tolerance with tolerogenic DC....
Nice to see how advanced DC therapeutics are now because of companies like $NWBO !https://t.co/LP9vdMVSQ1
CAR-T; clunky junk. Despite high initial response; high recurrence rate and in some cases 30+% die more quickly than if not treated. To me it’s another “over engineered” attempt to fuck with our own already sophisticated immune system. Enhance, not fool, Mother Nature $NWBO
— Gregory Zivic, MD (@metacollectiveG) October 27, 2023
Merck is known to shoot cannons at every thing that moves. They are into a lot of therapies. That they throw money at ADC, a potential chemo buster, does not in any way divert attention for the SPORE 1 project with DCVax-L or 14 other clinical trials in combo with dendritic cells
— 🇩🇰 The Danish Dude 🇩🇰 (@FlemmingBruce) October 26, 2023
BMY knows well about the efficacy of the combination of its Opdivo with DCVax-L and CSF1R-I.
— d_stock (@d_stock07734) October 26, 2023
It seems like BMY sponsored the research on this combination for five years with Dr. Liau as PI. BMY should know Merck's real motive behind the deal with Daiichi.https://t.co/3Qybo8cFXw pic.twitter.com/n1krIuKGg4
At 5k pts per month/ 7.1 multiple per below, $nwbo is a $86B company.
— annie post (@apwriter) October 26, 2023
Primary Brain Cancer stats:
Globally: 308K diagnosed in 2020.
US: 24k in 2023 est.
UK: 12K diagnosed per year, est. https://t.co/JbHEU9y1DO pic.twitter.com/Q3dFaMg6fH
#dcvax #allsolidtumors $nwbo #gbm https://t.co/CHClSiyvdd
— Peter Davis (@peter_brit) October 27, 2023
#dcvax #allsolidtumors $nwbo #gbm https://t.co/H99nrk65Fz
— Peter Davis (@peter_brit) October 27, 2023
What does this board certified Oncologist at the Harvard Medical School say about ADCs? They could eventually replace chemotherapy. But ADCs are not a replacement for a solid tumor therapeutic cancer vaccine like $NWBO #DCVax-L: https://t.co/aYt6LZQH1N pic.twitter.com/NbkoDbyqTA
— ATLnsider (@ATLnsider) October 25, 2023